Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Double-Blind Crossover Study of ER Niacin/Laropiprant/Simvastatin in Primary Hypercholesterolemia or Mixed Dyslipidemia
2011-001007-12Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of laropiprant in hypercholesterolemia, combined dyslipidaemia, sponsored by Merck & Co.. Started May 2011; status: terminated.
02
Drugs
laropiprant
03
Conditions
hypercholesterolemiacombined dyslipidaemia
Beyond the preview
Go deeper on 2011-001007-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001007-12.